Gender differences in cardiac hypertrophic remodeling

Annali dell'Istituto Superiore di Sanita

Volumn 52, Issue 2, 2016, Pages 223-229

  Patrizio, Mario ^a   Marano, Giuseppe ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Gender; Hypertrophy; Myocardial infarction; Myosin isoforms; Pressure overload

Indexed keywords

ANIMAL; CARDIOMEGALY; FEMALE; GENETICS; HEART VENTRICLE REMODELING; HUMAN; MALE; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ANIMALS; CARDIOMEGALY; FEMALE; HUMANS; MALE; MICE; SEX CHARACTERISTICS; VENTRICULAR REMODELING;

EID: 84979955478     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN_16_02_14     Document Type: Article

References (58)

1. World Health Organization. Noncommunicable disease (NCD) profiles. Available from: Www.who.int/nmh/coun- Trics/ita-en.pdf.
2. Levy D, Garrison RJ, Savage DD, Kanncl WB, Castclli WP. Left ventricular mass and incidence of coro- naryheart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110(2): 101-7. DOI:10.7326/0003-4819-110-2-101.
3. Srikanthan VS, Dunn FG. Hypertension and coronaiy artery disease. Med Clin North Am 1997;81(5):1147-63.
4. Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA, Castclli WP. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994;272(1):33-6. DOI:10.1001/jama.1994.03520010045030.
5. Kannel WB. Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res 1995;18(3): 181-96. DOI: 10.1291/hypres18.181.
6. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989;10(12):1110-4. DOI: 1110-1114.
7. de Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertension 1995;26(6):979-83. DOI: 10.1161/01.HYP.26.6.979.
8. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 2002;20(2):S34-8.
9. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J - Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure survey programme. A survey on the quality of care among patients with heart failure in Europe. Part 1. Patient characteristics and diagnosis. Eur Heart J 2003;24(5):442-63. DOI: 10.1016/S0195-668X(02)00823-0.
10. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004;43:317-32. DOI: 10. 1016/j.jacc.2003.07.046.
11. Regitz-Zagrosek V, Brokat S, Tschope C. Role of gender in heart failure with normal left ventricular ejection fraction. Prog Cardiovasc Dis 2007;49(4):241-51. DOI: 10.1016/j.pcad.2006.08.011.
12. Carroll JD, Carroll EP, Feldman T, Ward DM, Lang RM, McGaughey D, Karp RB. Sex- Associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992;86(4): 1099-107. DOI: 10.1161/01.CIR.86.4.1099.
13. Aurigemma GP, Silver KH, McLaughlin M, Mauser J, Gaasch WH. Impact of chamber geometry and gender on left ventricular systolic function in patients > 60 years of age with aortic stenosis. Am J Cardiol 1994;74(8):794-8.
14. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998;32(4):1118-25. DOI:10.1016/S0735-1097(98)00347-7.
15. Kostkiewicz M, Tracz W, Olszowska M, Podolec P, Drop D. Left ventricular geometry and function in patients with aortic stenosis: gender differences. J Am Coll Cardiol 1998;32(4):1118-25. DOI:10.1016/S0167-
16. Villar AV, Llano M, Cobo M, Exposito V, Merino R, Martin Duran R, Hurle MA, Nistal JF. Gender differences of echocardiography and gene expression patterns in human pressure overload left ventricular hypertrophy. JMol Cell Cardiol 2009;46(4):526-35. DOI:10.1016/j.yjmcc.2008.12.024.
17. Pfeffer JM, Pfeffer MA, Fletcher P, Fishbein MC, Braunwald E. Favorable effects of therapy on cardiac performance in spontaneously hypertensive rats. Am J Physiol 1982;242(5):776-84.
18. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol 1999;34(1):264-73. DOI:10.1016/S0735-1097(99)00165-5.
19. Rohde LE, Zhi G, Aranki SF, Beekel NE, Lee RT, Rcimold SC. Gender- Associated differences in left ventricular geometry in patients with aortic valve disease and effect of distinct overload subsets. Am J Cardiol 1997;80:475-80. DOI:10, 1016/S0002-9149(97)00398-6.
20. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 2002;8(2):101-7. DOI:10.1054/jcaf.2002.32195.
21. Dash R, Schmidt AG, Pathak A, Gcest MJ, Biniakicwicz D, Kadambi VJ, Hoit BD, Abraham WT, Kranias EG. Differential regulation of p38 mitogcn- Activatcd protein kinase mediates gender-dependent catccholaminc- induccd hypertrophy. Cardiovasc Res 2003;57(3):704-14. DOI:10.1016/S0008-6363(02)00772-1.
22. Xin HB, Senbonmatsu T, Cheng DS, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 2002;416(6878):334-8. DOI:10.1038/416334a'.
23. Berul CI, Christe ME, Aronovitz MJ, Scidman CE, Scidman JG, Mendelsohn ME. Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 1997;99(4):570-6. DOI:10.1172/JCI119197.
24. Cavasin MA, Tao Z, Menon S, Yang XP Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sci 2004;75:2181-92. DOI:10.1016/j.lfs.2004.04.024.
25. Wu JC, Nasscri BA, Bloch KD, Picard MH, Scherrer Crosbie M. Influence of sex on ventricular remodeling after myocardial infarction in mice. J Am Soc Echocardiogr 2003;16(11): 1158-62. DOI:10.1067/S0894-7317(03)00648-5.
26. Litwin SE, Katz SE, Litwin CM, Morgan JP, Douglas PS. Gender differences in postinfarction left ventricular remodeling. Cardiology 1999;91 (3): 173-83. DOI:10.1159/000006906.
27. Crabbc DL, Dipla K, Ambati S, Zafeiridis A, Gaughan JP, Houser SR, Margulies KB. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 2003;41(2):300-6. DOI:10.1016/S0735-1097(02)02710-9.
28. Biondi-Zoccai GG, Baldi A, Biasucci LM, Abbate A. Female gender, myocardial remodeling and cardiac failure: Arc women protected from increased myocardiocytc apoptosis? Ital Heart J 2004;5:498-504.
29. Guerra S, Leri A. Wang X, et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999;85:856-66. DOI:10.1161/01.RES.85.9.856.
30. Hullcy S, Grady D, Bush T, Furberg C, Hcrrington D, Riggs B, Vittinghoff E. Randomized trial of estrogenheart disease in postmenopausal women. Heart and Es- Trogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280(7):605-13. DOI:10.1001/jama.280.7.605.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Koopberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J - Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. DOI: 10.1001/jama.288.3.321.
32. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass iM, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S - Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291( 14): 1701-12. DOI:10.1001/jama.291.14.1701.
33. Alecrin IN, Aldrighi JM, Caldas MA, Gebara OC, Lopes NH, Ramires J A. Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic function. Heart 2004;90(7):777-81. DOI: 10.1136/hrt.2003.016493.
34. Fenkci S, Fenkci V, Yilmazer M, Serteser M, Koken T. Effects of short- Term transdermal hormone replacement therapy on glycacmic control, lipid metabolism, C-reactive protein and proteinuria in postmenopausal women with type 2 diabetes or hypertension. Hum Reprod 2003; 18(4):866-70. DOI: 10.1093/humrep/dcgl46.
35. Yildirir A, Yarali H, Kabakci G, Aybar F, Akgul E, Buku- lmez O. Hormone replacement therapy to improve left ventricular diastolic functions in healthy postmenopausal women. Int J Gynaecol Obstet 2001;75(3):273-8. DOI: 10.1016/S0020-7292(01)00469-6.
36. Ghali JK, Krause-Steinrauf HJ, Adams KF, Khan SS, Rosenberg YD, Yancy CW, Young JB, Goldman S, Peberdy MA, Lindenfeld J. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 2003;42(12):2128-34. DOI: 10.1016/j.jacc.2003.05.012.
37. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88(1): 107-15. DOI: 10.1161/01.CIR.88.1.107.
38. Reiser PJ, Portman MA, Ning XH, Schomish Moravec C. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles. Am J Physiol Heart Circ Physiol 2001;280(4):H1814-20.
39. Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report. Coronary heart disease events associated with hormone therapy in younger and older women. A meta- Analysis. J Gen Intern Med 2006;21(4):363-6. DOI: 10.1111/j.1525-1497.2006.00389.x.
40. Barton M, Meyer MR, Haas E. Hormone replacement therapy and atherosclerosis in postmenopausal women: docs aging limit therapeutic benefits? Arterioscler Thromb Vase Biol 2007;27(8): 1669-72. DOI: 10.1161/ATVBA- HA.106:130260.
41. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297(13): 1465-77. DOI:10.1001/jama.297.13.1465.
42. Murphy E. Estrogen signaling and cardiovascular disease. Circ Res 2011;109(6):687-96. DOI: 10.1161/CIR-CRESAHA. 110.236687.
43. Pines A, Fisman EZ, Shapira I, Drory Y, Weiss A, Eckstein N, Levo Y, Averbuch M, Motro M, Rotmensch HH, Ayalon D. Exercise echocardiography in postmenopausal hormone users with mild systemic hypertension. Am J Cardiol 1996;78(12): 1385-9. DOI:10.1016/S0002- 9149(96)00646-7.
44. Modena MG, Muia Jr. N, Aveta P, Molinari R, Rossi R. Effects of the transdermal 17 β-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 1999;34:1041-6. DOI: 10.1161/01.HYP.34.5.1041.
45. Miya Y, Sumino H, Ichikawa S, Nakamura T, Kanda T, Kumakura H, Takayama Y, Mizunuma H, Sakamaki T, Kurabayashi M. Effects of hormone replacement therapy on left ventricular hypertrophy and growth-promoting factors in hypertensive postmenopausal women. Hyper- Tens Res 2002;25(2): 153-9. DOI: 10.129/hypres.25.153.
46. Manhem K, Ghanoum B, Johansson M, Milsom I, Gustafsson H. Influence of chronic hormone replacement therapy on left ventricular mass and serum- ACE activity. Blood Press 2010;19(5):295-300. DOI: 10.3109/08037051.2010.488050.
47. van Eickels M, Grohe C, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-cstradiol attenuates the development of pressure-overload hypertrophy. Circulation 2001;104(12):1419-23. DOI: 10.1161/hc3601.095577.
48. Jazbutyte V, Arias-Loza PA, Hu K, Widder J, Govin- daraj V, von Poser-Klein C, Bauersachs J, Fritzemeier KH, Hegele-Hartung C, Neyses L, Ertl G, Pelzer T. Ligand-dependent activation of ER (beta) lowers blood pressure and attenuates cardiac hypertrophy in ovariectomized spontaneously hypertensive rats. Cardiovasc Res 2008;77(4):774-81. DOI: 10.1093/cvr/cvm081.
49. Patten RD, Pourati I, Aronovitz MJ, et al. 17p-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail 2008;14(3):245-53. DOI: 10.1016/j.cardfail.2007.10.024.
50. Pedram A, Razandi M, Aitkenhead M, Levin ER. Estrogen inhibits cardio myocyte hypertrophy in vrtro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1. J Biol Chem 2005;280(28):26339-48. DOI: 10.1074/jbc.M414409200.
51. Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS, Multiple domains of MCIP1 contribute to inhibition of calcineurin activity. J Biol Chem 2002;277:30401-7. DOI: 10.1074/jbc.M200123200.
52. Rothermel BA, McKinsey TA, Vega RB, Nicol RL, Mammen P, Yang J, Antos CL, Shelton JM, Bassel-Duby R, Olson EN, Williams RS. Myocytes-enriched calcineu- rin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2001;98:3328-33. DOI: 10.1074/jbc.M414409200.
53. Pedram A, Razandi M, Lubahn D, Liu J, Vannan M, Levin ER. Estrogen inhibits cardiac hypertrophy: Role of estrogen receptor-beta to inhibit calcineurin. Endocrinology 2008;149(7):3361-9. DOI: 10.1210/en.2008-0133.
54. Ma Y, Cheng WT, Wu S and Wong TM. Oestrogen confers cardio protection by suppressing:Ca2+/calmodulin-dependent protein kinase ii. Br J Pharmacol 2009; 157(5):705-15. DOI:10.1111/j.1476-5381.2009.00212.x.
55. Izumo S, Nadal-Ginard B, Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload Proc Natl Acad Sci USA 1988;85:339-43.
56. Reiser PJ, Moravcc CS. Sex differences in myosi heavy chain isoforms of human failing and non failing atria. Am J Physiol Heart Circ Physiol 2014;307(3):H265-72. DOI: 10.1152/ajphcart.00810.2013.
57. Patrizio M, Vago V, Musumeci M, Fecchi K, Sposi NM, Mattei E, Catalano L, Stati T, Marano G. cAMP-mediated beta- Adrenergic signaling negatively regulates Gq-coupled receptor-mediated fetal gene response in cardiomyocytes. J Mol Cell Cardiol 2008;45(6):761-9. DOI: 10.1016/j.yjmcc.2008.09.120.
58. Patrizio M, Musumeci M, Piccone A, Raggi C, Mattei E, Marano G. Hormonal regulation of β-myosin heavy chain expression in the mouse left ventricle. J Endocrinol 2013; 216(3):287-96. DOI: 10.153Q/JOE-12-0201.